China's Frontier Medical Devices – From Technological Catch-up to Global Leadership

From photon-counting CT to proton therapy, from surgical robots to brain-computer interfaces — China's medical device industry is no longer following. It is leading.

Introduction: A New Era for Chinese Medical Technology

China's medical device industry has undergone a remarkable transformation over the past decade. What was once a sector defined by low-cost manufacturing and imitation has evolved into a hub of genuine innovation, producing world-class technologies that are reshaping healthcare both domestically and globally.

The numbers tell the story. In 2025, China's National Medical Products Administration (NMPA) approved 76 innovative medical devices, a year-on-year increase of 17%, with 25 devices cleared through the priority approval process — representing a staggering 212.5% year-on-year increase. In the first half of 2026 alone, China's medical device exports reached $27.1 billion, up 12.4% year-on-year, with high-value products like surgical robots and nuclear medicine equipment far outpacing industry averages.

This article explores the most significant breakthroughs in China's frontier medical device sector — from photon-counting CT scanners to proton therapy systems, from surgical robots to brain-computer interfaces — and examines how these innovations are changing the face of healthcare.

I. Photon-Counting CT: The "Third Revolution" in Medical Imaging

Photon-counting CT has been hailed as the "third revolution" in medical imaging. Unlike conventional CT scanners that measure the total energy of X-rays, photon-counting detectors count individual photons and measure their energy levels, enabling unprecedented image quality at a fraction of the radiation dose.

NeuViz P10: The World's First Wide-Body Photon-Counting CT

In May 2026, Chinese manufacturer Neusoft Medical delivered the world's first wide-body photon-counting CT — the NeuViz P10. The device represents a decade of dedicated research and development, during which the team overcame critical technological barriers including cadmium-zinc-telluride (CZT) semiconductor detector technology.

Feature	Specification
Spatial resolution	0.1 mm — capable of clearly visualizing microscopic blood vessels and early-stage lesions
Temporal resolution	Significantly optimized for high-definition cardiac dynamic imaging
Radiation dose	Reduced by over 90% compared to conventional CT

The device has already completed clinical validation at top-tier institutions including West China Hospital, the First Hospital of China Medical University, and Beijing Tiantan Hospital, with applications spanning cardiovascular and cerebrovascular diseases, pulmonary nodule screening, and early cancer detection.

Significantly, Neusoft and another Chinese manufacturer, United Imaging, received simultaneous approvals for their photon-counting CT products in August 2025, breaking the long-standing foreign monopoly in this critical technology segment. As Neusoft's CEO Wu Shaojie remarked: "Ten years ago, almost no one believed this path could be successful."

II. Proton Therapy: Bringing Precision Cancer Treatment to More Patients

Proton therapy represents the gold standard in radiation oncology. Unlike conventional photon radiation, which deposits energy continuously along its path and damages healthy tissue, proton beams exploit the Bragg peak effect — traveling through the body with minimal energy release until they reach the tumor, then delivering a concentrated dose before stopping almost immediately. It is, in effect, a precision-guided missile against cancer.

Yet access to proton therapy in China has been severely constrained. According to the National Cancer Center, China sees approximately 4.8 million new cancer cases annually, with a substantial share in tumor types suitable for proton therapy. As of the end of 2025, fewer than 10 proton therapy centers were operational nationwide, treating fewer than 5,000 patients per year.

Capro-X1: China's First Domestically Produced Proton Therapy System

In August 2026, the Capro-X1, China's first domestically produced superconducting cyclotron proton therapy system, successfully completed its first clinical treatment. Developed by Hefei Branch Ion Medical Technology and Equipment Co., Ltd., the system leverages superconducting technology originally developed for nuclear fusion research at the Chinese Academy of Sciences' Institute of Plasma Physics — the same facility behind China's experimental "artificial sun" fusion reactor.

Key features of the Capro-X1:

• SC240 superconducting cyclotron accelerator — fully developed in-house
• Oversized irradiation field and 360-degree beam delivery capability
• Multi-modal 4D image-guided positioning that tracks minute tumor movements caused by breathing
• Full-chain domestication — from core components to complete integrated system

Cost implications: Proton therapy has long carried a luxury price tag in China — nearly 300,000 yuan (approximately $41,000) per treatment course, largely outside the reach of basic medical insurance. With full domestic production now achieved, industry expects per-course fees to fall to around 170,000 yuan (approximately $23,000) — a reduction of more than 40%.

Beyond building the machine, the company also led the development of the International Standard for Radiation Protection of Medical Proton Accelerators — moving China from technology follower to standard setter in the field.

Compact Proton Therapy Systems

In May 2026, NMPA also approved Mevion Medical's compact, integrated single-room proton therapy system — China's first domestically produced small-footprint proton therapy system. The system features significantly reduced equipment size, more flexible deployment, and shorter installation timelines, making proton therapy accessible to a broader range of hospitals.

III. Surgical Robots: From Follower to Global Competitor

China's surgical robotics sector has experienced explosive growth. As of August 25, 2026, China now holds 19 registration certificates for laparoscopic surgical robots, spanning 15 registration entities and approximately 12 brand systems. Of these, 18 carry the "Guo Xie Zhu Zhun" designation for domestically manufactured devices.

Market Transformation

The supply structure for laparoscopic robots in China has fundamentally shifted. What was once dominated absolutely by a single imported platform now includes a cohort of Chinese companies with complete master-slave laparoscopic robot systems. In the first half of 2026, provincial-level public hospital tenders for laparoscopic surgical robots saw domestic brands capture 63% of winning bids — the first time domestic products have surpassed imports in this mainstream market.

Export Surge

Chinese surgical robots are also going global. In the first half of 2026, China exported 480 million yuan ($71 million) of surgical robots — 3.3 times the previous year's figure — with export markets expanding from 23 to 49 countries and regions. Laparoscopic surgical robots have now obtained market access in over 100 countries and territories, with orders covering more than 70 countries. Overseas commercial installations exceed 220 units, accounting for approximately 80% of total installations, with overseas market revenue growing over 450% year-on-year.

Kunwu: The World's First "Five-in-One" Orthopedic Surgical Robot

At the 139th Canton Fair in May 2026, Yuanhua Robotics showcased its Kunwu "five-in-one" full-orthopedic surgical robot — a globally pioneering system that can cover five major orthopedic procedures: knee, hip, unicompartmental knee, spine, and trauma. This fills a worldwide technological gap in multi-indication orthopedic surgical robots.

The company also launched its HX Orthopedic-Specific Robotic Arm, featuring 100% independently controllable core components, robotic arm body, control system, underlying algorithms, and clinical software — completely breaking foreign monopolies and supply chain barriers.

Tuoling®: Remote Surgery Across 4,000 Kilometers

In August 2026, the Tuoling® Laparoscopic Surgical Robot developed by Tuodao Medical achieved a remarkable feat: completing three robot-assisted partial hepatectomies in a single day with the operating surgeon seated in Hangzhou and the patients lying on operating tables nearly 4,000 kilometers away in Alar, Xinjiang.

The system features proprietary force feedback instruments that provide surgeons with fine, realistic tactile feedback — complementing high-definition stereoscopic vision with a dual "visual plus tactile" sensory experience. The surgeries were performed without a single interruption or technical anomaly, demonstrating the reliability of Chinese surgical robotics for long-distance telemedicine.

Single-Port Systems

China now has three approved single-port laparoscopic surgical robot systems: the SR-ENS-600 from Shurui, the SP1000 from Edge Medical, and the SA-1000 from MicroPort's TouMai. These systems represent the next frontier in minimally invasive surgery, reducing incisions and accelerating patient recovery.

IV. AI-Powered Medical Imaging: From Single-Point Solutions to Systemic Integration

Artificial intelligence is transforming medical imaging in China, with AI-powered diagnostic tools now receiving regulatory approval and entering clinical practice at an accelerating pace.

DeepFAN: Asia's First AI-Assisted Pulmonary Nodule Differentiation Trial

In April 2026, a multicenter study led by Peking Union Medical College Hospital (PUMCH) completed Asia's first registered clinical trial of AI-assisted benign-malignant differentiation of pulmonary nodules. The DeepFAN deep learning model received NMPA Class III medical device registration — the highest regulatory classification for medical devices in China.

AI Medical Imaging Suite

At the 2026 China International Medical Equipment Fair (CMEF), United Imaging showcased its uAI MedTuring "one-scan, multi-diagnosis" AI agent for chest and brain imaging — a world-first innovation that enables comprehensive diagnostic assessment from a single scan. The company also demonstrated native AI deep integration across its product portfolio.

Neusoft released 13 AI products specifically optimized for photon-counting CT data, covering medical imaging annotation platforms, multi-modal medical AI platforms, and vascular imaging intelligent assessment systems.

AI Medical Device Commercialization Accelerates

In 2026 alone, multiple AI medical devices received NMPA Class III certification:

• Yice Technology — cervical cell digital pathology image-assisted diagnostic software (early 2026)
• Deshi Biotech — AI AutoVision chromosome karyotype-assisted diagnostic software (May 2026)
• Changmugu Medical — ROPA6 AI-powered full-orthopedic surgical robot (March 2026)

V. Extracorporeal Membrane Oxygenation (ECMO): Breaking Two Decades of Import Monopoly

ECMO — a life-support system that provides cardiac and respiratory support to patients with severe heart or lung failure — was long dominated by foreign manufacturers. That began to change in 2023, when Hannuo Medical's Lifemotion® ECMO system received domestic marketing authorization, ending a two-decade import monopoly.

Global Expansion

In early 2025, the Lifemotion® ECMO system received EU CE MDR certification, becoming the first domestically produced ECMO system to enter the international market. In March 2026, its independently developed single-use membrane oxygenator obtained U.S. FDA market access.

By the end of 2025, the Lifemotion® ECMO system had been installed in approximately 250 units, covering nearly 200 hospitals nationwide, with over 78% coverage of top-tier Class A tertiary hospitals including Beijing Anzhen Hospital, 301 Hospital, and West China Hospital.

Market Growth

China's ECMO system market reached 1.002 billion yuan (approximately $138 million) in 2025. According to Frost & Sullivan forecasts, the market is expected to grow from 960 million yuan in 2024 to 4.38 billion yuan by 2030, with a compound annual growth rate of 28.7%, and is projected to exceed 10 billion yuan ($1.4 billion) by 2035.

In June 2026, Beijing Aerospace Changfeng's ECMO system ACM9000 was accepted into China's priority review green channel for innovative medical devices.

VI. Brain-Computer Interfaces: From Laboratory to Clinical Reality

China's brain-computer interface (BCI) sector has seen accelerating momentum in 2026, with significant milestones across product registration, clinical trials, and production capacity building.

World's First Commercially Approved Implantable BCI

On March 13, 2026, NEO — an implantable brain-computer interface system developed by Borikang Medical Technology — received NMPA Class III medical device certification, becoming the world's first approved implantable BCI product.

On July 13, 2026, Huashan Hospital affiliated with Fudan University in Shanghai performed China's first commercial BCI implant surgery. A paralyzed patient became the first person in the world to receive a commercially approved brain-computer interface.

Market Projections

China's BCI market is projected to be valued at 6.14 billion yuan (approximately $904 million) by 2028. The technology has been designated a "future industry" in the Government Work Report and included in the outline of the 15th Five-Year Plan (2026-2030) as China aims to cultivate the sector into a new engine of economic growth.

In the first five months of 2026 alone, China's BCI sector saw over 30 financing events — exceeding the total for all of 2025.

VII. Capsule Endoscopy: Painless, AI-Powered Gastrointestinal Diagnosis

China has been a pioneer in capsule endoscopy technology. Jinshan Technology Group developed China's first and the world's second capsule endoscope, and later created the world's first fully automated navigation capsule endoscopy robot.

At the 139th Canton Fair in May 2026, Guangzhou Side Medical Technology demonstrated an intelligent capsule slightly larger than a regular pill. The capsule contains a high-definition camera that can scan the entire stomach in approximately 15 minutes — completing a painless, non-invasive gastroscopy. The capsule is naturally excreted afterward, with a 0.0002% probability of retention based on global experimental data.

The company has performed approximately 30,000 procedures worldwide with zero incidents.

AI-Enhanced Capsule Endoscopy

Chinese researchers have also developed INTELCAPE — an AI system for automated capsule endoscopy analysis that supports faster and more accurate diagnosis of Crohn's disease. The system was built and evaluated on 872 capsule endoscopy videos from two Chinese hospitals and demonstrated diagnostic accuracy comparable to experts while being 10 times faster.

VIII. The Broader Ecosystem: Policy Support and Industry Trends

China's medical device innovation boom is supported by a robust policy framework. In July 2026, the State Council officially released the "15th Five-Year Plan for National Health," which for the first time proposed "full-chain support for innovative drug and medical device development and application."

The NMPA's "Innovative Medical Device Special Review Process" has been instrumental in accelerating the pathway from development to market. The IND 30-day silent approval mechanism — already transforming drug development — is now being applied to select medical device categories.

Export Growth and Global Recognition

China's high-end medical equipment sector has moved beyond price competition to genuine technological competition. The shift is reflected in export data: in the first half of 2026, China's medical device exports reached $27.1 billion, up 12.4% year-on-year. Surgical robots, nuclear medicine equipment, and other high-value-added products far outpaced industry averages.

At the 32nd China International Medical Equipment Exhibition in August 2026, three major regional conferences were held concurrently — the China-Africa Hospital Development Conference, the Shanghai Cooperation Organization Medical Symposium, and the Gulf Cooperation Council High-Level Meeting — bringing together representatives from over 60 countries and regions. Photon-counting CT, proton therapy systems, and surgical robots were the focal points of international interest.

As one industry observer noted: "China has moved from competing on price to competing on technology."

Conclusion: From "Made in China" to "Innovated in China"

The transformation of China's medical device industry over the past decade has been extraordinary. What was once a sector defined by low-cost manufacturing has evolved into a hub of genuine technological innovation, producing world-class devices that are reshaping healthcare delivery.

From the NeuViz P10 — the world's first wide-body photon-counting CT — to the Capro-X1 proton therapy system; from the Kunwu five-in-one orthopedic surgical robot to the NEO brain-computer interface; from AI-powered diagnostic tools to domestically produced ECMO systems — Chinese medical device companies are no longer simply following global leaders. They are increasingly defining the frontier.

As China's medical device sector continues to mature, several trends will shape its future trajectory:

• Deep integration of AI across all device categories
• Continued globalization through exports and international partnerships
• Expansion of domestic manufacturing for critical components
• Growing clinical adoption driven by compelling cost-performance ratios

The era of Chinese medical device innovation has arrived. For patients in China and around the world, that means access to cutting-edge technology at more affordable prices — and ultimately, better healthcare outcomes.